45
Abbott Laboratories in the United States has developed a new type of weight loss drug Nometidine, which has been approved by the US FDA as an international patent with a dual mechanism of action. This weight loss drug is a serotonin and norepinephrine reuptake inhibitor, and its most important feature is that it combines changes in diet and behavior to increase body satiety and reduce energy intake by increasing body metabolism. Energy consumption, so as to correct the energy imbalance of the body and treat obesity symptomatically. The latest trial showed that within the first 6 months, the maximum weight loss was achieved and the effect was maintained for two years.
